=== PAGE 6 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Michele Yelmene
Xeris Pharmaceuticals, Inc.
NDA 214133 MA 14
                                                                                                        Page 6

Please direct your response to the undersigned at the **Food and Drug Administration,**
**Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-**
**B Ammendale Road, Beltsville, Maryland 20705-1266**. A courtesy copy can be sent by
facsimile to (301) 847-8444. Please refer to MA 14 in addition to the NDA number in all
future correspondence relating to this particular matter. All correspondence should include a
subject line that clearly identifies the submission as a Response to Untitled Letter. You are
encouraged, but not required, to submit your response in eCTD format. All correspondence
submitted in response to this letter should be placed under eCTD Heading 1.15.1.6.
Additionally, the response submission should be coded as an Amendment to eCTD
Sequence 5013 under NDA 214133. Questions related to the submission of your response
letter should be emailed to the OPDP RPM at CDER-OPDP-RPM@fda.hhs.gov.

                                                                               Sincerely,

                                                               {See appended electronic signature page}

                                                               Ankur Kalola, PharmD, RAC
                                                               Regulatory Review Officer
                                                               Division of Advertising & Promotion Review 2
                                                               Office of Prescription Drug Promotion

                                                               {See appended electronic signature page}

                                                               Susannah K. Oâ€™Donnell, MPH, RAC
                                                               Team Leader
                                                               Division of Advertising & Promotion Review 2
                                                               Office of Prescription Drug Promotion
Reference ID: 5186528
